miglustat has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, K; Honda, T; Kasahara, J; Kasuya, Y; Kurumiya, E; Murayama, T; Nakamura, H; Sakamoto, Y; Takabatake, M; Tatsumi, K; Watanabe, K; Yamazaki, A; Yamazaki, R; Yoshino, I; Zhou, Y | 1 |
1 other study(ies) available for miglustat and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
N-butyldeoxynojirimycin (miglustat) ameliorates pulmonary fibrosis through inhibition of nuclear translocation of Smad2/3.
Topics: Animals; Bleomycin; Fibroblasts; Idiopathic Pulmonary Fibrosis; Lung; Lung Injury; Mice; Mice, Inbred C57BL; Myofibroblasts; Transforming Growth Factor beta1 | 2023 |